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Niche, a specialized physiological microenvironment in which stem cells reside, plays a 
crucial role in the maintenance of stem cell characteristics such as pluripotency and self-
renewal. The stem cell niche is composed of a group of cells providing a physical anchoring 
site for stem cells with the interaction of adhesion molecules between stem cells and niche 
cells or extracellular matrices (Li & Xie, 2005). The niche controls stem cell number, 
proliferation and fate of determination. Thus, a better understanding of the nature of stem 
cells and their niche will lead to alternative treatment strategies for various diseases, 
including malignant tumors. 
 More than a decade ago, the existence of a rare population with both stem cell-like 
properties and tumor initiating capability was first identified in acute myeloid leukemia 
and, subsequently, in several solid tumors. These populations with stem cell-like properties 
were termed ‘cancer stem cells (CSCs)’, indicating that only a subset of cancer cells were 
tumorigenic and able to initiate and produce the bulk of tumors, thus also termed ‘tumor 
initiating cells’ (Reya, et al., 2001). Although CSCs may not harbor all of the properties of 
normal stem cells, they are characterized by their ability both to self-renew and to 
differentiate into certain cell types with limited potential for differentiation and 
proliferation.  
Some functional environments, namely ‘cancer stem cell niche’, a counterpart of normal 
stem cell niche, may support CSCs like normal stem cells (Sneddon & Werb, 2007). There are 
similarities in the maintenance system for the stem cell niches between normal and cancer 
stem cells such as the presence of molecules involved in adhesion and chemokine-
chemokine receptor interaction. On the other hand, it might be possible that the behaviors of 
CSCs and normal stem cells are regulated by the niche to different degrees (Li & Neaves, 
2006). The niche is supposed to control the balance between quiescence and 
proliferation/differentiation of the stem cells. In cancers, the characteristics of the niche that 
function to support proliferation and differentiation could be more dominant than is 
necessary to maintain quiescence. However, the similarities and differences between the 
normal stem cell niche and the tumor microenvironment are still unclear. 
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Mesenchymal stem cells (MSCs) are non-hematopoietic stromal cells, mainly existing in the 
bone marrow and possibly in various tissues, that are capable of differentiating into and 
contributing to the regeneration of mesenchymal tissues such as bone, cartilage, muscles, 
tendons and adipose tissue (Chamberlain, et al. 2007).  
MSCs secrete several paracrine factors including chemoattractants for endothelial lineage 
cells, monocytes and macrophages as well as inflammatory factors such as various 
chemokines and interleukins (Kinnaird, et al. 2004). MSCs could be involved in cell survival, 
invasion, motility, and interactions with the extracellular matrix through the chemokine 
signaling that results in the transcription of target genes in cancer cells as well as 
macrophages and lymphocytes (Roorda, et al. 2010). MSCs are also considered to be the 
source of tumor-associated fibroblasts (TAFs) that are important components of tumor 
stroma. Therefore, MSCs play an important role in orchestrating the tumor 
microenvironment through angiogenesis, modulation of both immune system and tumor 
stromal architecture. 
MSCs may also be involved in the metastatic process (Karnoub, et al. 2007). Tumor 
metastasis requires numerous cell types and molecules to undertake sequential, multi-step 
processes such as intravasation and circulation, extravasation and migration, and 
angiogenesis to form the metastatic foci (Honoki, et al. 2007). The metastatic process is 
considered to be very complex and inefficient as only ~2% of disseminated cells form 
micrometastasis and only ~0.02% of cells develop into macrometastasis. One of the possible 
explanations for this inefficiency is the need for the metastatic cells to find an appropriate 
environment for themselves. MSCs are thought to play some roles in providing the homing 
sites for those cells, leading to the establishment of the metastatic foci, either directly or 
indirectly through the cooperation with extracellular matrices and other cells like 
macrophages and vascular endothelial cells. 
The composition of the niche is very complex and varied in specific tissues even in normal 
conditions. Thus, the interaction of CSCs with their niche could be even more complex. The 
current review describes the potential roles of MSCs in tumor progression as the 
constituents of tumor stroma and niche that affect the cell fate of CSCs. Although the 
environments constituting a true cancer stem cell niche are still not fully elucidated, the 
exploration of the precise role of MSCs in cancer could potentially uncover the pathogenesis 
and mechanisms of progression such as metastasis. This is likely to lead to novel targeted 
therapies against cancers. 
2. Role of mesenchymal stem cells in tumor microenvironment 
The tumor stroma consists of a compilation of cells and matrices including 
fibroblasts/myofibroblasts, immune/inflamatory cells, blood vessels, connective tissues and 
extracellular matrix (ECM). Tumor-associated stromal cells like fibroblasts/myofibroblasts, 
immune/inflamatory cells and vascular endothelial cells are considered to be recruited from 
surrounding normal tissue or from circulation, and contribute to diverse aspects of tumor 
development and progression. Mesenchymal stem cells (MSCs) have also been 
demonstrated thier homing ability to the primary tumor site and metastatic sites in several 
studies (Studeny, et al. 2002, Dwyer, et al. 2007, Hall, et al. 2007), and possibly play a role as 
a co-conspirator of tumor development. MSCs may interact with tumor cells to promote 
tumor growth directly or indirectly through autocrine/paracrine manners with soluble 
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factors as well as anigiogenesis. In addition, MSCs could be the origin of tumor-associated 
fibroblasts or myofibroblasts contributing to the formation of tumor microenvironment that 
eventually lead to expansion and progression of tumors (Spaeth, et al. 2009).  
It is possible that MSCs have a potencial to provide a specific microenvironment or a niche 
for cancer stem cells by themselves or as a source of its components. The interaction 
between stem cells and their specific microenvironment/niche cells will enhance the 
understanding of cancer development, including metastasis. We will firstly discuss here the 
general concept of stem cell and niche, then expand it to cancer stem cells and finally focus 
on the role of mesenchymal stem cells in the tumor microenvironment. 
2.1 Stem cell and niche 
Stem cells are the subset of cells that have the capacity to self-renew and generate 
functionally differentiated mature cells. Adult stem cells, including mesenchymal stem cells, 
are an essential component of tissue homeostasis, which support tissue regeneration, and 
are considered to reside in a special microenvironment. The fate of stem cells is regulated 
with a delicate balance between self-renewal and differentiation by both intrinsic programs 
and extrinsic signals from the environment. There are various intrinsic programs that 
control stem cell self-renewal and potency, such as Hox genes family for hematopoietic stem 
cells and Bmi, a polycomb family, for hematopoietic and neural systems (Kyba, et al. 2002, 
Lessard, et al. 2003, Park, et al, 2003). These intrinsic genetic programs have been shown to 
be subject to environmental regulation. Therefore, environmental regulatory signals are 
required to stem cell properties as well as intrinsic genetic programs. 
Schofield first proposed the ‘niche’ hypothesis to define some specific microenvironment 
that supports stem cells (Schofield, 1978). The niche is a physical anchoring site for stem 
cells, composed of a group of cells in a special location that functions to maintain stem cells. 
In recent years, niches have been identified for stem cells in the intestinal, neural, epidermal, 
and hematopoietic system. The niche maintains stem cells primarily in a quiescent state and 
the stem cells become activated to divide and proliferate when a stimulating signal reaches 
to them (He, et al. 2005). The niche generates extrinsic factors that control stem cell fate 
through regulatory signal molecules, including sonic hedgehog, Wnts, bone morphogenic 
proteins (BMPs), fibroblast growth factors (FGFs), and Notch (Ivanova, et al. 2002). Stem 
cells exhibit an asymmetric division, indicating that one daughter cell is maintained in the 
niche as a stem cell, in terms of self- renew, while other daughter cell leaves the niche to 
proliferate and differentiate into a matured cell. Above extrinsic factors orchestrate the 
appropriate regulation of stem cell self-renewal and lineage commitment.  
The component of niche or niche cells and involved environmental signals differ in tissue by 
tissue. For instance, hematopoietic stem cell niche is considered to be composed of 
osteoblastic and perivascular niche (Fig.1), and Wnt, Notch and BMP signals play a role in 
self-renewal, differentiation and proliferation (Reya, et al. 2003, Duncan, et al. 2005, Zhang, 
et al. 2003). While, for intestinal stem cells, they are located at the 4th or 5th position above 
the Paneth cells, and mesenchymal cells adjunct to the intestinal stem cells function as the 
niche. There, Wnt signalling plays a positive role in promoting stem cell activation/self-
renewal and crypt cell fate, in contrast, BMP signalling restricts stem cell activation/self-
renewal and crypt cell fate (van de Wetering, et al. 2002, He, et al. 2004).  
When the balance between these controls is disrupted, stem cell may proliferate without 
restraint that might lead to tumorignesis.  
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Fig. 1. Model of hemtopoietic stem cell (HSC) niche. The HSC niche is located on the surface 
of trabecular bone, and spindle-shaped N-cadherin-positive osteoblastic cell plays an 
important role to regulate HSC behavior, with an interaction of different types of stromal 
cells by secreting different microenvironmental signals 
2.2 Normal stem cell and cancer stem cell, and their niches 
Recent numerous researches have generated a new concept of tumor progression modeling 
for the cancer growth based on the cancer stem cell hypothesis (Fig. 2, Dick, 2008). The 
properties of cancer tissues have been defined the following characteristics; (i) limitless 
capacity to replicate, (ii) self-sufficiency for growth signals, (iii) insensitivity to antigrowth 
signals, (iv) evasion of apoptosis, (v) sustained angiogenesis, (vi) tissue invasion and 
metastasis (Hanahan et al., 2000). Since majority of those characteristic are considerably 
sharing with normal stem cell properties, the hypothesis has emerged indicating that tumor 
tissue, like normal tissue, is continuously repopulated from pools of self-renewing stem–like 
cells, termed as ‘cancer stem cells’ (Table 1). Cancer stem cells exist as a side population on 
the top of hierarchy within tumors, possessing stem-like properties like self-renewing and 





Table 1. Comparison between normal somatic and cancer stem cell 
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As described above, in normal adult tissues, stem cells depend on the integration of both 
cell-intrinsic and cell-extrinsic factors for proper, homeostatic tissue maintenance. It is likely 
that there is a functional microenvironment to support cancer stem cells, a counterpart of 
normal stem cells and their niche. 
Involvements of several factors have been indicated in the interaction between cancer stem 
cells and their microenvironment. Dick and colleague and Van Etten and colleague 
respectively showed that CD44 is essential for the homing and engraftment of the cancer 
stem cells to the niche for acute myeloid leukemia and chronic myeloid leukemia (Jin, et al. 
2006, Krause, et al. 2006). Interestingly, the molecular mechanisms of leukemia cell homing 
to the niche resemble those of the interaction between normal hematopoietic stem cells and 
the vascular niche. 
Another example is that CD133-positive brain tumor cells, that contain cancer stem cells, 
selectively adhere to the endothelial cells that possibly form a vascular niche (Calabrese, et 
al. 2007). CD133-positive cells have been extensively studied in colon, prostate and 
pancreatic cancers, and further study will reveal the molecular mechanism underlying the 
relationship between CD133-positve cancer stem cells and the niche. 
 
Fig. 2. Hypothesis for the development of cancer stem cells. Stem cell and/or progenitor 
cells with accumulated genetic alteration show sustained or reacquired self-renewal 
capacity, and at certain point, these cells, so called ‘cancer stem cells’ give rise to more 
differentiated, but not fully matured cancer cells with aggressive proliferation 
Several cellular components have also been indicated as the cancer stem cell niche with 
specific signal transduction pathways. For instance, endothelial cells in the vasculature of 
the brain maintain neural stem cell properties, in part through Notch signalling (Shen, et al. 
2004), and this is the same as the brain cancer stem cells and their vascular niche (Hovinga, 
et al. 2010). Another extensively studied example is the mesenchymal stromal cells in cancer 
stem cell niche in the intestine. In normal intestine, stem cells reside in a stem cell niche 
composed of epithelial cells and mesenchymal cells of the myofibroblast lineage lining the 
crypt. Currently, the Wnt signalling cascade is considered to be a prominent force 
controlling cell proliferation, differentiation, and apoptosis to maintain stem cell fate at this 
region (Clevers, 2006). As the counterpart of the normal intestinal stem cell niche, tumor -
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associated myofibroblasts and mesenchymal stem cells are shown to be major components 
of the colon cancer stroma (Mishra, et al. 2008). Colon cancer stem cells have been shown 
high Wnt activity and orchestrated by myofibroblasts residing in the tumor stroma through 
the hepatocellular growth factor pathways (Vermeulen, et al. 2010).  
These data suggest that there is a strong link between cancer stem cells and the 
microenvironment as well as that between normal stem cells and their niche, courageously 
indicating the presence of cancer stem cell niche. 
However, unlike normal stem cell niche, the behaviours of cancer stem cells might be 
regulated by the niche to different degrees (Li & Neaves, 2006). The stem cell niche under 
normal conditions predominantly inhibits stem cells from both proliferation and 
differentiation, and a transient proliferating signal is required to activate tissue regeneration. 
Contrary, in tumors, cancer stem cells could be self-sufficient to undergo uncontrolled 
proliferation due to their internal mutations and/or changes in the niche signals. This leads 
the hypothesis of cancer stem cell niche as an environment with dominant signals to tumor 
cell proliferation and growth more favourably compared to the normal stem cell niche. 
2.3 Homing of mesenchymal stem cells in tumor stroma 
The concept of adult mesenchymal stem cells (MSCs) was first proposed almost four 
decades ago (Friedenstein, et al. 1970), then have been extensively investigated on molecular 
and functional characterization of these cells. Although the definition of MSCs is commonly 
accepted as bone marrow-derived, adherent to plastic surface, with the ability of self-renew 
and differentiation into bone, cartilage and adipose tissues, the specific marker or 
phenotype to definitively identify or describe these cells are still lacking. This is because 
MSCs reside not only in bone marrow but also in many other tissues through the entire 
body, and presumably MSC-like cells or MSC subsets exist with retaining MSC features. 
It has been shown that MSCs can be recruited to the site of wound healing to repair 
damaged tissues, and so as to tumors like breast cancer, colon cancer, ovarian cancer, 
glioma, melanoma and osteosarcoma (Karnoub, et al. 2007, Studeny, et al. 2004, Nakamizo, 
et al. 2005, Komorava, et al. 2006, Djouad, et al. 2003, Brune, et al. 2010). These MSCs exhibit 
specialized features tailored for each particular tissue. As described above, tumor-associated 
fibroblast (TAFs), including myofibroblast, are part of tumor stroma that functionally and 
structurally supports tumor progression and development in conjunction with other 
components like vasculature, inflammatory cells and extracellular matrix (Sullivan, et al. 
2008). There are also several evidences indicating that MSCs invade tumors and function as 
TAFs (Direkze, et al. 2004). TAFs have been shown to promote tumor progression through 
the production of growth factors like TGF-┚, chemotactic factors like SDF-1 and monocyte 
chemotactic protein-1, angiogenic factors like VEGF and matrix metalloproteinases (MMPs) 
leading invasion and spread of tumor cells. Although the origin of tumor stromal fibroblasts 
is not fully elucidated, it is possible to consider some of these stromal cells including TAFs 
as a ‘specialized’ subset of MSCs. (Haniffa, et al. 2007, Stagg, 2008). Therefore, either MSCs 
themselves or specialized MSCs like TAFs in the stroma are key players directly or 
indirectly involved in tumor progression (Fig. 3). 
As cancers are sometimes referred to as ‘wounds that never heal’ (Dvorac, 1986), the 
microenviroment of a solid tumor is very similar to the environment of an injured tissue. 
Thus, tumor growth is often associated with a variety of cells and factors in a similar 
manner with the wound healing and tissue repair sites. Several studies have shown the 
involvment of MSCs for injured tissue repair. In that process, chemokines and chemokine 
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receptors such as CXCR4, CXCR12 and CCL5 have been indicated in the tissue-homing 
ability of MSCs (Dwyer, et al. 2007), and TGF-┚ family and Wnt signals play important roles 
in MSCs-mediated tissue repair (Mishra, et al. 2005). Like these factors, many players 
involved in MSCs for tumor progression are very similar to the wound repair response 
(Dvorac, 1986). 
 
Fig. 3. Hypothesis for the involvement of mesnechymal stem cells in tumor progression. 
Mesnechymal stem cells migrate in tumor tissue and incorporate into TAFs. TAFs stimulate 
cancer cell proliferation through the growth factor signals like TGF-┚. MSC itself or TAFs 
could participate in angiogenesis by secreting factors like VEGF and MMPS 
Another contribution of MSCs in tumor development would be pro-invasive potential 
homing to the metastatic site for cancer cells, possibly the cancer stem cells, to create a so 
called ‘premetastatic niche’ (Kanoub, et al. 2007). The ability of a tumor to metastasize may 
depend on the ability to establish distant niches suitable for them as well as the 
characteristics of tumor cells themselves. MSCs colonize the premetastatic niche before 
metastatic tumor cells have arrived in response to signals from the tumor cells. Factors like 
CCL5, SDF-1, VEGF and MMPs are also involved in this phenomenon (Kaplan, et al. 2007).  
Although numerous studies indicated the homing ability of MSCs to primary and metastatic 
site, one might argue that the homing of MSCs might not be completely tissue specific and 
could distribute to a wide range of organs. So far, no data are available where MSCs 
detected in tumor stroma originate from whether the local mesenchyme or bone marrow. 
Therefore, detailed mechanisms of participating molecules involved in homing of MSCs to 
tumor site should be further investigated for the development of therapies targeting MSC-
tumor cell interaction. 
2.4 Role of mesenchymal stem cells in tumor progression 
Intrinsic capabilities of tumor cell itself have been focused on the research of tumor 
progression including invasion and metastasis. On the other hand, recent advances of the 
research on tumor microenvironment indicate that components of heterogeneous 
population of stromal cells such as fibroblasts, immune cells can enhance tumor progression 
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with their dynamic interactions. MSCs are considered to be involved in many aspects as the 
origin of tumor stromal fibroblasts, source of soluble factors to attract immune cells and 
angiogenesis. 
In fact, the relationship between MSCs and tumor cells could be dual. Thus, both primary 
and metastatic tumor cells actively attract MSCs from either bone marrow or surrounding 
tissues where they contribute to the tumor microenvironment as described above; vice 
versa, MSCs stimulate tumor cells to produce a variety of cytokines and other growth 
factors. 
2.4.1 An immunomodulator in the process of tumor development  
Immunosuppressive properties of MSCs contribute in part to the tumor developments. 
MSCs have been shown to suppress the lymphocyte proliferative response in a broad way 
regarding the types of stimulation and of lymphocyte population (Di Nicola, et al. 2002, 
Djouad, et al. 2003). A number of mechanisms have been reported for these effects, such as 
secretion of anti-inflammatory factors (Rasmusson, 2006), modulation of the function of the 
major immune cell population (Glennie, et al. 2005), cell cycle arrest in the G0/G1 phase on 
B lymphocyte (Corcione, et al. 2006), modulation of development and function of cytotoxic T 
cells and dendritic cells (Rasmusson, et al. 2003, Jiang, et al. 2005), inhibition of interferon-γ 
production by activated natural killer cells (Aggarwal & Pittenger, 2005).  
These mechanisms could be clue to explain how tumor cells evade the immune system. One 
might hypothesize that tumor cells can harness MSCs that manipulate the immune system 
through several ways described above, and eventually evade the immune attack (Yen & 
Yen, 2008). 
Beside immunosuppressive effects, recruitment of tumor infiltrating macrophages or tumor 
associated macrophages (TAMs) could be another role of MSCs. The role of TAMs is 
multifaceted, as not only providing supportive microenvironment for malignant cells but 
also inducing oncogenic mutations in surrounding cells in earliest carcinogenesis (Pelham, 
et al. 2006). TAMs could be a heterogeneous population and whose possible common origin 
would be monocytes actively recruited into tumor site. Monocytes can migrate in response 
to chemokines such as CCL2, CCL5, CXCL8/IL-8 and SDF-1, and also to growth factors like 
vascular endothelial growth factor (VEGF) produced by MSCs as well as tumor cell itself 
(Murdoch, et al. 2004, Barleon, et al. 1996). Migrated monocytes differentiate into TAMs 
(Mantovani, et al. 2002), and eventually contribute to tumor progression via production of 
growth factors and regulation of pro-angiogenic switch (Lin, et al. 2006). 
2.4.2 A source of soluble factors involved in angiogenesis 
The formation of tumor vessels requires the proliferation and directional migration of 
vascular endothelial cells through basement membrane and stroma toward pro-angiogenic 
stimuli, such as soluble chemoattractants like VEGF, basic fibroblast growth factor (bFGF) 
and angiopoietins (Ang-1). 
Specialized MSCs in tumor stroma, like TAFs as described above, play an important role for 
the formation of tumor vessels. MSCs and/or TAFs produce several pro-angiogenic factors 
including VEGF, FGFs, Ang-1, platelet derived growth factor (PDGF) as well as cytokines 
such as IL-6, 8 and TNF-┙ (Kinnaird, et al. 2004). These molecules are involved in the 
recruitment and activation of endothelial cells through paracrine manner as well as direct 
cell – cell contacts (Zacharek, et al. 2007).  
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Tumor angiogenesis requires active remodeling and integration of new cells into existing 
structures and is the result of a complex tumor – stroma crosstalk, involving multiple 
ligands and cellular signaling pathways. SDF-1/CXCL12 axis and MMPs are critical players 
to recruit and engraftment of marrow derived endothelial progenitors for growth of new 
vessels from pre-existing vasculature (Genis, et al. 2006).  
MMPs secreted from stromal cells including MSCs and TAFs play the diverse roles in not 
only degradation of the extracellular matrices, but also cleavage of proteinases, chemokines 
and chemotactic factors, growth factors and cell surface receptors, and cell matrix adhesion 
molecules (Coussens, et al. 2002) to participate in restructuring tumor microenvironments 
including angiogenesis. Proteolytic cleavage of angiogenic factor, secreted protein acidic 
rich in cysteine (SPARC)/osteonectin is also indirect effect of MMPs to regulate the tumor 
angiogenesis (Sangaletti, et al. 2003).   
Then, VEGF from MSCs and TAFs in tumor stroma stimulate budding of existing vessels 
and proliferation of new vascular channels. Although VEGF is a potent vascular growth 
factor and the main stimulus for the formation of tumor vessels, it is implicated in many 
aspects of cancer growth such as extracellular matrix remodeling and generation of 
inflammatory cytokines and other molecules involved in the pro-angiogenic and pre-
metastatic niche (Kaplan, et al. 2005). The main stimulus for secretion of VEGF is hypoxia, 
which results in the recruitment of endothelial progenitor and mesenchymal stem cells to 
sites of ischemia, that in turn additional VEGF production leading to tumor angiogenesis 
and generation of tumor stroma (Okuyama, et al. 2006). 
2.4.3 A source of niche cells for cancer cells / cancer stem cells 
For normal stem cells, the microenvironment or niche where they reside is important to 
maintain the stemness, and to regulate proliferation and differentiation. The similarities 
between normal stem cells and cancer stem cells as shown in Table I could extend the 
attractive concept of stem cell niche to the presence of cancer stem cell niche. There have 
been several studies indicating the specialized cancer stem cell niches may participate in the 
tumor development (Calabrese, et al. 2007, Gilbertson & Rich, 2007), and is considered to 
play an important role in virtually every aspect of the tumorigenic cascade including the 
metastatic process as well as drug resistance.  
Usually, metastasis occurs in an organ-selective manner described as the ‘seed and soil’ 
hypothesis which indicate that local microenvironment of specific organs seems to be more 
receptive to particular tumor cells than other organs. Thus, disseminated tumor cells need to 
meet a suitable microenvironment in order to survive and initiate a secondary tumor. The 
metastatic process is very complicated and inefficient with multi-steps such as intravasation, 
circulation, arrest, extravasation migration and angiogenesis (Honoki, et al. 2007). Tumor 
stromal cells including MSCs might be involved in several phases of the metastatic process 
with the interaction of cancer stem cells (Fig. 4). 
Mesenchyaml stem cells have the ability to enhance growth and metastasis of certain 
cancers like colon cancer (Shinagawa, et al. 2010), and have been proposed to give rise to 
tumor-associated fibroblasts that further promote tumor progression. The metastatic 
potential of breast cancer cells and osteosarcoma cells has also been shown to be strongly 
enhanced when coinjected with MSCs through the paracrine signaling events (Karnoub, et 
al. 2007, Xu, et al. 2009). In this context, MSC-derived CCL5 appears to be an essential factor 
to enhance the growth and invasiveness of tumor cells. IL-6 from MSCs is also involved in 
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growth promotion effect for osteosarcoma cells (Bian, et al. 2010). MSCs also produce 
chemoattractant proteins like SDF-1 and MCP-1 that attract circulating tumor cells like B 
leukemia cells, breast cancer cells (Burger & Kipps, 2002, Molloy, et al. 2009).  
Transition to TAFs from MSCs has been shown to contribute to the tumor growth through 
fibrovascular network expansion and production of tumor-stimulating paracrine factors 
(Spaeth, E.L. 2009). Activated fibroblasts or TAFs have been found also at liver metastasis, 
where they promote tumor outgrowth (Olaso, et al. 1997). Fibroblast activation is probably 
involved in priming the premetastatic niche with fibronectin deposits (Kaplan, et al 2005) to 
attract tumor cells to their preferable sites for metastasis. Moreover, the infiltration of 
activated fibroblasts or myofibroblasts precedes the recruitment of vascular endothelial cells 
in the hypoxic avascular metastatic environment, and they produce VEGF to promote 
angiogenesis and transition to a vascular stage (Olaso, et al. 2003). In addition to paracrine 
signaling, MSCs protect tumor cells against apoptosis and promote initial tumor cell 
proliferation mainly by direct cell – cell contact interactions (Roorda, B.D. 2010). All of these 
data suggest that MSCs are directly or indirectly involved in the metastatic process as the 
source of niche for metastatic tumor cells. 
 
 
Fig. 4. Possible involvement of tumor stromal cells including MSCs/TAFs in clustering 
metastatic model. Metastatic tumor cells, possibly including cancer stem cells, complete a 
very complicated metastatic process cooperating with tumor stromal cells. Soluble factors 
such as MMPs, CCL5, CXCR4, SDF-1, IL-6 and VEGF secreted from MSCs/TAFs participate 
in the metastatic process 
Besides of the effect on tumor progression, tumor stromal cells may contribute to the drug 
resistance through complex mechanisms such as the direct cell contact, the interaction of 
extracellular matrices (ECM) and soluble factors (Nefedova, et al. 2003). Soluble factors that 
mediate drug resistance are produced by a dynamic interaction between tumor cells and 
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stromal cells. IL-6 and SDF-1 are known to mediate resistance to various chemotoxics in 
hematological and epithelial cancers. IL-6 activates c-FLIP and STAT3 signaling that result 
in protecting tumor cells from TNF-related apoptosis-inducing ligand (TRAIL) and FAS-
mediated apoptosis (Duan, Z, et al. 2006, Perez, et al. 2008). SDF-1 increases β1 integrin-
mediated adhesion of myeloma and small lung cell carcinoma, leading to drug resistance in 
ECM-adhered tumor cells (Sanz-Rodriguez, et al. 2001, Hartmann, et al. 2005). Integrin-
mediated adhesion increases the activation of cytokine signaling pathways and also leads to 
a state of tumor dormancy. For instance, β1 integrin amplifies IL-6-induced STAT3 signaling 
(Shain, et al. 2009) as well as leading tumor cells to cell cycle arrest (White, et al. 2006) that 
result in drug resistance eventually. β1 integrin-mediated adhesion to ECM components 
also leads to cell cycle arrest through p21 and p27 up-regulation (Fischer, et al. 2005), which 
contribute to drug resistance (St. Croix, et al. 1996).  
Taken together, although there are no direct evidences indicating MSCs or TAFs provide the 
niche for cancer stem cells nor they are not the only player for cancer stem cell niche, these 
tumor stromal cells could have bystander effects to participate in tumor progression as the 
niche cells, providing dominant signals to tumor cell proliferation and growth, and recessive 
signals to lead cancer cells into the dormant state with the interaction of ECM. Both signals 
eventually contribute to tumor progression such as metastasis and drug resistance. 
2.5 Therapeutic implications of mesenchymal stem cells in cancer 
There are several possible different ways to imply targeting MSCs into therapeutic purpose. 
Firstly, targeting paracrine loop of soluble factors could disrupt the interaction between 
tumor cells and MSCs, which contributed many aspects of tumor progression and drug 
resistance. Inhibition of VEGF receptor tyrosine kinase activity and receptor tyrosine kinase 
for FGF blocks a paracrine IL-6 production by stromal cells, and leads to apoptosis of tumor 
cells (Lin, et al. 2002, Bisping, et al. 2009). Small molecule inhibitor of SDF-1 receptor CXCR4 
increases the chemo-sensitivity of leukemic cells and prolongs survival of leukemic patients 
(Zeng, et al. 2008). Since both IL-6 and SDF-1 also play an important role in the 
microenvironment of solid tumors as described above, the therapeutic approaches that 
disrupt communication between tumor cells and stromal cells such as MSCs/TAFs could be 
feasible against solid malignancies. 
 Secondly, MSCs that migrate to tumor site would be useful as carriers of oncolytic or 
immune-modulatory adenoviruses or as direct target of ‘activated’ or genetically altered 
stromal cells. MSCs have been engineered in a number of different ways as the vehicles 
delivering cytotoxic drugs, stimulating the immune response or blocking angiogenesis. 
MSCs modified to express IFN-β and γ were able to inhibit tumor growth (Studeny, et al. 
2004, Li, et al. 2006). MSCs infected with adeno- or retrovirus encoding IL-12 showed 
inhibitory effects on tumor growth through the activation of NK cells and CD8+ T cells 
(Elzaouk, et al. 2006). Bone marrow-derived progenitors with suicide gene integration used 
as delivery vehicles have also been shown to reduce tumor size and vascularity (Komarova, 
et al. 2006). Tumor-associated angiogenesis was inhibited by MSCs infected with adenovirus 
to express NK4 via antagonizing HGF-c-met signalling pathway (Kanehira, et al. 2007).  
 Several studies suggested the direct inhibitory effects of MSC itself against tumor growth 
of, for instance, mouse Lewis lung carcinoma, B16 melanoma (Maestroni, et al. 1999), and rat 
colon cancer model (Ohlsson, et al. 2003). Involvements of non-inflammatory cytokines and 
Akt activity have been suggested on these effects, however, the exact factors mediating the 
anti-tumor activities of MSCs have not been clearly identified.  
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Although MSCs have a potential in cell-based anti-cancer therapy, the safety of using MSCs 
is still questionable, because homing of MSCs is not selective and genetically engineered 
MSCs could undergo malignant transformation. Thus, the precise action of MSCs will need 
to be studied to develop the safe and specific treatments. 
Another possible target would be the homing mechanisms by which cancer stem cells 
migrate to metastatic sites or the factors that govern the cellular dynamics within their 
‘pathological niche’ or ‘cancer stem cell niche’, where MSCs possibly play a role in several 
aspects of tumor progression.  
Further study will be required to understand the details of components, regulation and 
interaction between cancer stem cell and their niche to develop a novel treatment strategy. 
3. Conclusions 
Pro-tumorigenic contribution of MSCs is still not fully uncovered. This is in part explained 
by the presence of heterogeneous population due to the lack of exact definition of MSC 
population, and the complexity of their interaction with tumor cells and the large range of 
cytokines and growth factors. However, a number of evidences suggest that MSCs are 
actively recruited into tumor site, and contribute to tumor microenvironment as either 
themselves or as the tumor-associated fibroblasts. They directly or indirectly regulate tumor 
cell proliferation, differentiation, immune tolerance, angiogenesis, metastasis and drug 
resistance through the interaction with numerous cytokines and growth factors as well as 
providing niche to the cancer cells or cancer stem cells in cooperated with ECM. Although 
MSCs can be friends or foes of tumor cells, depending on their constituents of population 
including the origin and stage of differentiation and also the type of tumor cells to be 
interact with, further investigation will define the role of MSCs in tumor progression that 
leads to novel strategy for cancer therapy.  
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